Gujarat is likely to attract investments worth Rs 3,000 crore in the pharma sector, of these, Sanand is estimated to attract investment of Rs 2,200 crore. The applications for licences for greenfield and brownfield investments have been made with the Gujarat Food and Drug Control Administration (FDCA).

Of these, consumer goods major Procter and Gamble (P&G) India is planning to invest Rs 2,000 crore in a personal healthcare manufacturing facility at Sanand in Gujarat. The facility will produce psyllium husk-based products in its digestive and wellness segment.

P&G is also set to invest in manufacturing topical cough and cold products at the said location. An additional Rs 150 crore would be invested for products marketed under the Vicks brand, and the company will manufacture inhalers and vaporub, among other products at the facility. The company has acquired the land for the proposed plant.

In the past three years, FDCA has approved licences for around 800 new units. Out of these units, most of the plants would be established by micro, small, and medium enterprises (MSMEs), which will come up in Valsad, Bharuch, Kadi, Vadodara and Rajkot, among other places. Entities such as PI Industries and Omkar Chemical Industries have already applied for environmental clearance (EC) to start construction of API and formulations manufacturing units in the state.